Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM

Sagar Lonial, MD, FACP, discusses factors to consider when selecting later lines of therapy for patients with triple-class refractory multiple myeloma (MM).

An expert in multiple myeloma considers rationale for targeting BCMA and discusses recent FDA approval of belantamab mafodotin based on the DREAMM 2 trial.

A key opinion leader in medical oncology reviews optical and hematological toxicities of belantamab mafodotin and discusses how to mitigate adverse events.

Sagar Lonial, MD, FACP, emphasizes the importance of partnering with eye care specialists to manage optical toxicities of patients taking belantamab mafodotin.

A leading authority in multiple myeloma comments on the future of belantamab mafodotin, such as combination therapy based on the DREAMM 5 and DREAMM 8 trials.